Please note that some of the meeting sessions will include data specific to products from Alnylam®

YOUR INVITATION

Tuesday 6 October - Friday 9 October 2020
Virtual event, "live" from the Karolinska Institute, Stockholm, Sweden
(2 hour evening session each day)

HEREDITARY ATTR AMYLOIDOSIS: EXPLORING POSSIBILITIES, TRANSFORMING OUTCOMES

"To raise new questions, new possibilities, to regard old problems from a new angle requires creative imagination and marks real advance in science."

— Albert Einstein

CLICK **HERE** TO REGISTER YOUR INTEREST IN JOINING THE MEETING

PLEASE CONTACT YOUR LOCAL ALNYLAM REPRESENTATIVE FOR MORE INFORMATION

For healthcare professionals only. This meeting is organized and funded by Alnylam® Pharmaceuticals
Please note that some of the meeting sessions will include data specific to products from Alnylam®
ATTR, transthyretin amyloidosis; hATTR, hereditary transthyretin amyloidosis.
09-2020 TTR02-ESP-00115

Alnylam® PHARMACEUTICALS
CHALLENGE ACCEPTED

WELCOME FROM THE CHAIRS

Dear Colleagues,

It is our pleasure to invite you to attend an Alnylam organized and funded four-day meeting entitled **'Hereditary ATTR amyloidosis: Exploring possibilities, transforming outcomes'** which will take place on the evenings of Tuesday 6 October - Friday 9 October 2020. The meeting will be virtual, hosted "live" from the Karolinska Institute, Stockholm, Sweden, home of the Nobel Assembly, and one of the world's foremost medical universities.

This interactive, educational event focuses on translating the latest scientific innovations into improved outcomes for patients with hereditary ATTR amyloidosis.

The highly engaging scientific programme was developed in collaboration with an expert international faculty of cardiologists, neurologists and gastroenterologists, and aims to advance best practice in the management of this complex disease.

Through a series of presentations and example case studies, experts from specialist centres across Europe will be challenged to answer key questions on how to overcome the significant unmet needs of patients with hereditary ATTR amyloidosis. Debate will focus on how multidisciplinary collaboration might facilitate the early diagnosis and monitoring of patients, management of disease progression and when treatment should be initiated. We encourage you to take part in the interactive sessions giving you the opportunity to share your experiences and network with colleagues.

We look forward to you virtually joining us at the Karolinska Institute for this important international gathering of experts.

Prof. David Adams
APHP, National Reference Center for FAP,
University of Paris-Saclay, Le Kremlin-Bicêtre, France

Prof. Teresa Coelho
Unidade Corino de Andrade,
Centro Hospitalar Universitário do Porto, Portugal

Prof. Arnt Kristen
Kardiovaskuläres Zentrum,
Darmstadt, Germany

Prof. Ole Suhr
Institutionen för Folkhälsa och Klinisk Medicin,
Umeå Universitet, Sweden

For healthcare professionals only. This meeting is organized and funded by Alnylam® Pharmaceuticals
Please note that some of the meeting sessions will include data specific to products from Alnylam®
ATTR, transthyretin amyloidosis; hATTR, hereditary transthyretin amyloidosis.
09-2020 TTR02-ESP-00115

Alnylam® PHARMACEUTICALS
CHALLENGE ACCEPTED

Meeting objectives

- Optimize the **early identification and diagnosis** of people with hATTR amyloidosis
- Understand **disease burden, clinical presentation** and effectively **monitor and manage disease progression**
- Raise awareness of the role of **emerging treatments** in overcoming significant **unmet patient needs**
- Facilitate the **delivery of integrated care** and **advance best practice** in the management of hATTR amyloidosis
- Promote a collaborative, **multidisciplinary approach** to ensure the patient is at the heart of care

Day 1 virtual agenda: 18:00–20:00 (CEST)

MEETING INTRODUCTION: Exploring possibilities and transforming outcomes in hATTR amyloidosis	
18:00–18:15	**Welcome and introduction from the Chair** David Adams
18:15–18:30	**Keynote: In conversation – 'What matters to people with hATTR amyloidosis'** Carlos Heras-Palou
18:30–18:35	**Opening video: One patient's journey – The natural history of hATTR amyloidosis**
18:35–18:55	**Plenary: Overview of pathogenesis and pathophysiology of the disease** Per Westermark
18:55–19:00	**BREAK:** Virtual coffee break
THE BURDEN OF hATTR AMYLOIDOSIS	
19:00–19:25	**Plenary: The burden of disease progression – Reducing the disability burden and life years lost** David Adams (Chair)
19:25–19:45	**Plenary: The burden of disease progression – The cost of care** Bouke Hazenberg
19:45–19:55	**Audience Q&A and panel discussion: Changing expectations on the disability burden and life years lost** David Adams (Chair), Bouke Hazenberg, Per Westermark
19:55–20:00	**Summary** David Adams (Chair)

For healthcare professionals only. This meeting is organized and funded by Alnylam® Pharmaceuticals
Please note that some of the meeting sessions will include data specific to products from Alnylam®
ATTR, transthyretin amyloidosis; hATTR, hereditary transthyretin amyloidosis.
09-2020 TTR02-ESP-00115

Alnylam® PHARMACEUTICALS
CHALLENGE ACCEPTED

Day 2 virtual agenda: 18:00–20:00 (CEST)

EARLY IDENTIFICATION AND DIAGNOSIS	
18:00–18:05	**Welcome and introduction** Arnt Kristen (Chair)
18:05–18:10	**Opening video: One patient's journey to diagnosis**
18:10–18:35	**Plenary: hATTR amyloidosis – Clinical presentation and patient identification** Lucía Galán, Carol Whelan
18:35–19:05	**Fireside discussion: Diagnosis – Challenges and opportunities** Arnt Kristen (Chair), Julian Gillmore, Katrin Hahn/Fabian Knebel, Astrid Terkelsen, Carol Whelan
19:05–19:10	**BREAK:** Virtual coffee break
GENETIC TESTING AND EARLY TREATMENT	
19:10–19:15	**Introduction** Ole Suhr (Chair)
19:15–19:30	**Plenary: Genetic testing and implications for the family** João Freixo, Arndt Rolfs
19:30-19:45	**Plenary: Initiating early treatment after diagnosis** Laura Obici, Diana Bonderman
19:45-19:55	**Discussion: Genetic testing and early treatment** Ole Suhr (chair), João Freixo, Arndt Rolfs, Laura Obici, Diana Bonderman
19:55–20:00	**Summary** Ole Suhr (Chair)

Day 3 virtual agenda: 18:00–20:00 (CEST)

CHALLENGING DISEASE PROGRESSION	
18:00–18:05	**Welcome and introduction** Teresa Coelho (Chair)
18:05–18:10	**Opening video: One patient's journey – Recording disease progression**
18:10–18:40	**Plenary: Disease progression – What does it look like and is it acceptable?** Michel Slama
18:40–19:00	**Fireside discussion: Optimizing ongoing monitoring and management** Teresa Coelho (Chair), Fabian Knebel, Michel Slama
19:00–19:05	**Summary** Teresa Coelho (Chair)
19:05–19:10	**BREAK:** Virtual coffee break
OPTIMIZING PATIENT MANAGEMENT – ORGANIZATION OF CARE	
19:10–19:15	**Introduction** Teresa Coelho (Chair)
19:15–19:55	**Building a multidisciplinary approach** Julian Gillmore, Katrin Hahn/Fabian Knebel, Theodoros Kyriakides, Michel Slama
19:55–20:00	**Summary** Teresa Coelho (Chair)

For healthcare professionals only. This meeting is organized and funded by Alnylam® Pharmaceuticals
Please note that some of the meeting sessions will include data specific to products from Alnylam®
ATTR, transthyretin amyloidosis; hATTR, hereditary transthyretin amyloidosis.
09-2020 TTR02-ESP-00115

Alnylam® PHARMACEUTICALS
CHALLENGE ACCEPTED

Day 4 virtual agenda: 17:40–20:00 (CEST)

OPTIMIZING TREATMENT OF hATTR AMYLOIDOSIS	
17:40-17:45	**Welcome and introduction** Arnt Kristen (Chair)
17:45-17:50	**Opening video: One patient's journey – Changing expectations of treatment**
17:50-19:00	**Plenary: hATTR amyloidosis – Treatment optimization for multisystem disease** Julian Gillmore, Michael Polydefkis, Marcus Urey, Teresa Coelho
19:00-19:15	**Disease transforming therapies in hATTR amyloidosis: The economic case** TBC
19:15-19:20	**BREAK:** Virtual coffee break
19:20-19:40	**Fireside discussion: Treatment optimization for patients with multisystem disease** Arnt Kristen (Chair), Julian Gillmore, Michael Polydefkis, Marcus Urey
19:40-19:55	**Keynote: The future management of hATTR amyloidosis** Michael Polydefkis
19:55-20:00	**Summary and meeting close** Arnt Kristen (Chair)

PLUS ON DEMAND SESSIONS AVAILABLE DURING THE MEETING

Faculty

Professor David Adams
Neurology (France)

Professor Diana Bonderman
Cardiology (Austria)

Professor Teresa Coelho
Neurology (Portugal)

Mr Tobias Degsell
CEO, Combiner (Sweden)

Dr João Freixo
Clinical genetics (Portugal)

Dr Lucía Galán
Neurology (Spain)

Professor Julian Gillmore
Nephrology (UK)

Dr Katrin Hahn
Neurology (Germany)

Professor Bouke Hazenberg
Rheumatology (Netherlands)

Mr Carlos Heras-Palou
Patient advocate (UK)

Professor Fabian Knebel
Cardiology (Germany)

Professor Arnt Kristen
Cardiology (Germany)

Professor Theodoros Kyriakides
Neurology (Cyprus)

Dr Laura Obici
Internal medicine (Italy)

Professor Michael Polydefkis
Neurology (USA)

Professor Arndt Rolfs
Neurology (Germany)

Professor Michel Slama
Cardiology (France)

Professor Ole Suhr
Gastroenterology (Sweden)

Professor Astrid Terkelsen
Neurology (Denmark)

Professor Marcus Urey
Cardiology (USA)

Professor Per Westermark
Pathology (Sweden)

Dr Carol Whelan
Cardiology (UK)

Alnylam® PHARMACEUTICALS
CHALLENGE ACCEPTED